Navitor Pharmaceuticals Inc.
Targeting mTORC1 to treat disease
This article was originally published in Start Up
Navitor Pharmaceuticals Inc.’s drug discovery efforts are focused on producing compounds that can selectively dampen or bolster mTORC1 activity. Increased activity of mTORC1 has been linked to metabolic, autoimmune, neurodegenerative, and chronic inflammatory diseases.
You may also be interested in...
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.
X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.
Over the past five years, pharma companies have cast an increasingly wide research net in search of cancer immunotherapy drug combinations that can help patients who have failed monotherapies.